EGFR and colon carcinoma: Finally, the colon carcinoma specific (though not overrepresented) c.38G > A (p.G13D) substitution was previously found to associate with response to anti-EGFR antibodies and better overall survival (OS) and progression free survival (PFS)16, though the degree of response to anti-EGFR treatment is still under debate19.